Hypothesis

Aging reduces adipose eosinophil IL‑4 secretion and alters eosinophil‑derived exosome cargo, leading to diminished IL‑4‑exosome delivery to muscle satellite cells. Concurrently, elevated IL‑5 signaling in tissue eosinophils promotes loading of inhibitory miRNAs (e.g., miR‑21) into exosomes, suppressing satellite cell PPARδ‑mediated fatty acid oxidation and impairing regenerative capacity. We hypothesize that selective IL‑5 blockade in aged mice restores eosinophil exosome IL‑4 content and reduces inhibitory miRNA loading, thereby re‑activating PPARδ in satellite cells, enhancing oxidative metabolism, and rescuing age‑related sarcopenia. It's well established that eosinophils decline with age in visceral fat, but we don't yet know how this impacts muscle.

Predictions

1. IL‑5 antagonism (e.g., anti‑IL‑5 antibody) in 24‑month‑old mice will increase circulating eosinophil exosomes bearing IL‑4 and decrease exosomal miR‑21 levels compared with IgG‑treated controls.
2. Muscle satellite cells isolated from IL‑5‑treated aged mice will show higher PPARδ activity, increased fatty acid oxidation (measured by palmitate oxidation assay), and improved proliferation/differentiation in vitro.
3. Functional readouts (grip strength, voluntary wheel running, treadmill endurance) will be significantly improved in IL‑5‑treated aged mice, matching levels seen in young controls.
4. Pharmacologic or genetic blockade of exosome release (e.g., GW4869 or conditional knockout of Rab27a in eosinophils) will abolish the beneficial effects of IL‑5 antagonism on muscle metabolism and performance.

Experimental Design

• Animals: Young (3‑month) and aged (24‑month) C57BL/6 mice; eosinophil‑specific Cre (Epx‑Cre) crossed with floxed Rab27a for exosome‑deficient eosinophils; IL‑5Rα knockout as genetic control.
• Treatments: Aged mice receive anti‑IL‑5 antibody (or isotype control) weekly for 6 weeks; a subgroup receives GW4869 to inhibit exosome synthesis.
• Readouts:
  • Circulating eosinophil exosomes isolated by ultracentrifugation; IL‑4 and miR‑21 quantified by ELISA and qRT‑PCR.
  • Satellite cell PPARδ activity assessed via luciferase reporter and target gene (Cpt1a, Fabp1) expression.
  • Metabolic flux: Seahorse palmitate‑oxidation assay.
  • In vivo muscle function: grip strength, voluntary wheel running distance, treadmill time to exhaustion.
  • Histology: central nucleation, fibrosis (Masson’s trichrome), and FAP activation (PDGFRα staining).
• Controls: Young mice receiving IgG; aged IgG; aged anti‑IL‑5 + exosome blockade.

Potential Outcomes and Interpretation

• If predictions hold: Increased IL‑4‑exosome delivery and reduced miR‑21 in exosomes after IL‑5 blockade would support the notion that IL‑5 modulates eosinophil exosome composition, linking adipose eosinophil aging to muscle satellite cell metabolism. Rescue of satellite cell PPARδ activity and muscle function would demonstrate a mechanistic axis whereby eosinophil‑derived exosomes mediate systemic rejuvenation beyond adipose tissue.
• If exosome blockade abolishes benefits: This would confirm that eosinophil exosomes are necessary effectors, shifting focus from soluble cytokines to vesicle‑mediated communication.
• If IL‑5 antagonism fails to alter exosome cargo or muscle outcomes: The hypothesis would be falsified, suggesting that eosinophil effects on muscle are independent of IL‑5‑driven exosome remodeling or that other eosinophil‑derived factors dominate in aging muscle.

Such results would clarify whether targeting the IL‑5/eosinophil exosome axis can be a viable strategy to counteract sarcopenia and frailty in older individuals.